310 Shares in Cencora, Inc. (NYSE:COR) Bought by Northwest Investment Counselors LLC

Northwest Investment Counselors LLC purchased a new stake in shares of Cencora, Inc. (NYSE:COR) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 310 shares of the company’s stock, valued at approximately $75,000.

A number of other hedge funds also recently bought and sold shares of the company. NBC Securities Inc. acquired a new position in shares of Cencora during the 1st quarter worth about $976,000. Park Avenue Securities LLC acquired a new position in shares of Cencora during the first quarter worth approximately $2,114,000. Cullen Investment Group LTD. bought a new stake in shares of Cencora in the first quarter valued at approximately $924,000. Vanguard Group Inc. acquired a new stake in shares of Cencora in the fourth quarter worth $4,212,508,000. Finally, Alaska Permanent Fund Corp bought a new position in Cencora during the first quarter worth $1,819,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Price Performance

Shares of Cencora stock opened at $239.32 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. The stock has a market capitalization of $47.73 billion, a price-to-earnings ratio of 26.18, a P/E/G ratio of 1.64 and a beta of 0.48. Cencora, Inc. has a 1-year low of $171.65 and a 1-year high of $246.75. The firm’s 50-day moving average price is $229.61 and its two-hundred day moving average price is $227.34.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, topping the consensus estimate of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The firm had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. During the same period in the prior year, the firm earned $3.50 earnings per share. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts predict that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were given a dividend of $0.51 per share. The ex-dividend date was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.85%. Cencora’s payout ratio is 22.32%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. SVB Leerink began coverage on Cencora in a research report on Monday, February 26th. They set an “outperform” rating and a $261.00 price objective on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Cencora in a research report on Monday, February 26th. Robert W. Baird boosted their price target on shares of Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Finally, Citigroup raised their price objective on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $233.90.

Insider Transactions at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven H. Collis sold 10,754 shares of the stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total transaction of $2,553,859.92. Following the completion of the transaction, the chief executive officer now owns 285,088 shares in the company, valued at $67,702,698.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,956,675 shares of company stock worth $422,352,056. Corporate insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.